CRISPR/Cas Biosensing System: Opportunities and Challenges

Presented By: Guozhen Liu, PhD

Speaker Biography: Guozhen Liu, a professor of Biomedical Engineering, School of Medicine, the Chinese University of Hong Kong, Shenzhen, is leading a research team working on Integrated Devices and Intelligent Diagnostics (ID2). Her team focuses on interdisciplinary and translational research to develop cutting-edge technologies applicable for point-of-care diagnostics, microfluidic biochips, intelligent nanoparticles, and medical devices to accurately diagnose, manage and prevent chronic diseases (such as diabetes, Parkinson's disease). Prof Liu has published (less than)150 peer-reviewed journal papers, 3 book chapters and lodged 16 patents. Prof Liu was awarded the prestigious Australian Research Council Future Fellowship (2016), the Academic Excellence Award for transdisciplinary research (2017), and George Sweet Award for Women in Quantitative Biomedical Science (2020). Prof Liu’s research career has alternated between industrial and academic research. Prof Liu’s industrial experience includes over four years spent as R&D Manager, China for AgaMatrix Inc. to make medical devices for diabetes. She has closely engaged with many international biotechnology companies, such as AstraZeneca, BioLegend, AgaMatrix, Regeneus.

Webinar: CRISPR/Cas Biosensing System: Opportunities and Challenges

Webinar Abstract: Rather than being famous in gene editing field only, by revealing the collateral cleavage activity of Cas12a, Cas13a, Cas14 effectors, and more, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated (Cas) (i.e., CRISPR/Cas) systems has recently received significant credits in the field of diagnostics with the capability of developing novel CRISPR/Cas medicated biosensors with superior sensitivity and specificity. Exciting development of CRISPR/Cas based biosensors has thrived quickly in recent 2-3 years, and a variety of different biosensing systems have now been developed successfully such as SHERLOCK, SHERLOCKv2, DETECTR, HOLMES, etc. Despite the features of high sensitivity and specificity, all the known CRISPR/Cas involved biosensing systems are specialized to detect nucleic acids. Recent studies have demonstrated that CRISPR/Cas systems are providing excellent biosensing capability for detection of non-nucleic acids, such as small molecules, proteins, exosomes, metal ions, et al. Although the most popular signal read-out in CRISPR/Cas biosensors is fluorescence, recently, various signal read-out modalities such as colorimetric, electrochemiluminescence, electrochemical and electrical have been applied in CRISPR/Cas biosensing systems. Furthermore, they can be multiplexed, enabling a single diagnostic test to identify the presence of multiple targets. Coupling of the CRISPR/Cas detection with lateral flow device-based signal readout, will allow for the highly sensitive and accurate in-field detection of pathogens and viruses. ...

Labroots on Social:
Facebook:   / labrootsinc  
Twitter:   / labroots  
LinkedIn:   / labroots  
Instagram:   / labrootsinc  
Pinterest:   / labroots  
SnapChat: labroots_inc